Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
EA4181
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
- NCT04115631 ↗
- Active, not recruiting
- ECOG-ACRIN Cancer Research Group
- Focused
We haven't built an HCP commentary report on EA4181 (acalabrutinib, bendamustine hydrochloride and 3 more in Liver Lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EA4181 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 4 | |
| Podcasts | 3 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Liver Lymphoma; Mantle Cell Lymphoma
- Interventions
- Acalabrutinib; Bendamustine; Bendamustine Hydrochloride; Cytarabine; Rituximab
- Arms
- Arm A (bendamustine, rituximab, cytarabine) · Experimental
- Arm B (acalabrutinib, bendamustine, rituximab, cytarabine) · Experimental
- Arm C (acalabrutinib, bendamustine, rituximab) · Experimental
- Enrollment
- 360
- Primary outcomes
- Composite of positron emission tomography (PET)/computed tomography (CT) complete response (CR) and peripheral blood (PB) minimal residual disease (MRD) negative rate
- Sponsor
- ECOG-ACRIN Cancer Research Group with National Cancer Institute (NCI)
- Start
- Dec 13, 2019
- Primary completion
- Dec 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04115631 · updated Sep 14, 2026
Publications
linked from the registry- Patel DA, Wan F, Trinkaus K, Guy DG, Edwin N, Watkins M, Bartlett NL, Cashen A, Fehniger TA, Ghobadi A, Shah NM, Kahl BS. Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies. Clin Lymphoma Myeloma Leuk. 2023 Jul;23(7):552-560. doi: 10.1016/j.clml.2023.04.003. Epub 2023 Apr 24. PubMed 37183115